These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 4369891)

  • 1. Correlation of pretreatment serum nonprotein-bound cortisol and total 17-hydroxycorticosteroid values with survival in patients with prostatic cancer.
    Blackard CE; Byar DP; Seal US; Doe RP
    N Engl J Med; 1974 Oct; 291(15):751-5. PubMed ID: 4369891
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum corticosteroid-binding globulin, cortisol, and nonprotein-bound cortisol levels in patients receiving estrogen for carcinoma of the prostate.
    Blackard CE; Doe RP; Seal US
    Invest Urol; 1973 Nov; 11(3):194-7. PubMed ID: 4584161
    [No Abstract]   [Full Text] [Related]  

  • 3. Endocrine treatment of cancer of the prostate.
    Madsen PO; Pedersen JF; Knuth OE
    Wis Med J; 1970 Jul; 69(7):177-81. PubMed ID: 4916084
    [No Abstract]   [Full Text] [Related]  

  • 4. Response of serum cholesterol and triglycerides to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
    Seal US; Doe RP; Byar DP; Corle DK
    Cancer; 1976 Sep; 38(3):1095-107. PubMed ID: 182347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
    Seal US; Doe RP; Byar DP; Corle DK
    Cancer; 1976 Sep; 38(3):1108-17. PubMed ID: 182348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of pre-treatment serum 17-hydroxycorticosteroid values with survival in patients with prostatic cancer.
    Blackard CE; Byar DP; Seal US; Doe RP
    J Urol; 1975 Apr; 113(4):517-20. PubMed ID: 163929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer of the prostate.
    N Engl J Med; 1968 Apr; 278(15):848-9. PubMed ID: 5642506
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group.
    Surg Gynecol Obstet; 1967 May; 124(5):1011-7. PubMed ID: 6022476
    [No Abstract]   [Full Text] [Related]  

  • 9. Response of serum haptoglobin to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
    Seal US; Doe RP; Byar DP; Corle DK
    Cancer; 1978 Oct; 42(4):1720-9. PubMed ID: 213184
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hormone therapy of cancer of the prostate gland].
    Madsen PO; Pedersen IF; Knut OE
    Urol Nefrol (Mosk); 1970; 35(3):25-8. PubMed ID: 4915239
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC].
    Pavone-Macaluso M; Martínez-Piñeiro JA; de Voogt H; Lardennois B; Nasta A; Zolfanelli R; Barasolo E; De Pauw M; Suciu S; Sulvester R
    Arch Esp Urol; 1982; 35(5):304-11. PubMed ID: 6217788
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer of the prostate:estrogen therapy: natural conjugated estrogen vs. Stillbestrol: A point of view.
    Kaplan L
    Rev Surg; 1968; 25(5):323-9. PubMed ID: 4301296
    [No Abstract]   [Full Text] [Related]  

  • 13. Estrogen and survival data in carcinoma of the prostate.
    Bennett AH; Dowd JB; Harrison JH
    Surg Gynecol Obstet; 1970 Mar; 130(3):505-8. PubMed ID: 4905115
    [No Abstract]   [Full Text] [Related]  

  • 14. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
    de Voogt HJ; Pavone-Macaluso M; Smith PH; de Pauw M; Suciu S
    Prog Clin Biol Res; 1988; 260():111-7. PubMed ID: 2966403
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761.
    Pavone-Macaluso M; Ingargiola GB; de Voogt H; Viggiano G; Barasolo E; Lardennois B; De Pauw M; Sylvester R
    Prog Clin Biol Res; 1987; 243A():379-82. PubMed ID: 2958862
    [No Abstract]   [Full Text] [Related]  

  • 16. The EORTC Phase III trials in prostatic cancer.
    Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
    Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
    [No Abstract]   [Full Text] [Related]  

  • 17. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
    Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hormone treatment in the prostatic cancer].
    Madsen PO; Pedersen JF; Knuth OE
    Urologe; 1969; 8(6):330-3. PubMed ID: 5405377
    [No Abstract]   [Full Text] [Related]  

  • 19. Elevated nonprotein-bound cortisol (NPC) in pregnancy, during estrogen administration and in carcinoma of the prostate.
    Doe RP; Dickinson P; Zinneman HH; Seal US
    J Clin Endocrinol Metab; 1969 Jun; 29(6):757-66. PubMed ID: 5783579
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of clinically localized prostatic cancer--endocrine therapy].
    Hirano A
    Hinyokika Kiyo; 1996 Oct; 42(10):829-32. PubMed ID: 8951483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.